Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701911 | 0.93 | ABCB11 (0.30) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL22108953 | 0.87 | ALOX5AP (0.32) | — | |
| SCHEMBL22108951 | 0.85 | NAAA (0.34) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL21386576 | 0.85 | NAAA (0.34) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL28232289 | 0.80 | — | — | |
| SCHEMBL624867 | 0.80 | CYP3A4 (0.38) | ALDH1A1CYP3A4HPGDTDP1 | |
| SCHEMBL29564714 | 0.79 | ALDH1A1 (0.38) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL156589 | 0.79 | ALDH1A1 (0.38) | ABCB11ALDH1A1NR3C1CYP1A2CYP3A4 | |
| SCHEMBL22108969 | 0.79 | NAAA (0.32) | — | |
| SCHEMBL22108901 | 0.79 | NAAA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12466818-B2 | Thienyl-aniline compounds for treatment of dermal disorders | NFLECTION THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| CN-119215031-A | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-113645964-B | Arylaniline and heteroaryl aniline compounds for fetal treatment | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-113660931-B | Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer | 恩福莱克逊治疗有限公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-117551073-A | Thienylaniline compounds for the treatment of dermatological disorders | 恩福莱克逊治疗有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20100179124-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2010-07-15 | — | — | US | disclosed |
| EP-2183253-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB Pharma, S.A. (BE) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009153554-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-12-23 | — | — | WO | disclosed |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009093009-A1 | FUSED TRICYCLIC THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093008-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-30 | — | — | WO | disclosed |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | US | disclosed |
| EP-2054417-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB Pharma S.A. (BE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009013462-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466818-B2 | Thienyl-aniline compounds for treatment of dermal disorders | TYR, NAT1, BRAF | ABCB11 3433/4885ALDH1A1 176/4885NR3C1 412/4885 |
| US-20090264411-A1 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | MAPK15, MOK, MAPK14 | ABCB11 4152/4885ALDH1A1 3718/4885NR3C1 1367/4885 |
| US-20100179124-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | ABCB11 4256/4885ALDH1A1 2577/4885NR3C1 1207/4885 |
| US-20090149437-A1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | MAP3K6, MAPK1, MAP3K20 | ABCB11 4256/4885ALDH1A1 2577/4885NR3C1 1207/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | ABCB11 715/4885ALDH1A1 479/4885NR3C1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.